Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Risk Score to Stratify High-risk PanNETs
Sponsor: Fudan University
Summary
Considerable heterogeneity exists in the risk of recurrence after curative resection of pancreatic neuroendocrine tumors (PanNETs). Current clinicopathological parameters (e.g., grade, TNM stage) have limited capacity for individualized risk stratification. There is an urgent need for a clinically accessible and operationally simple predictive tools to identify high-risk PanNETs for optimizing personalized postoperative treatment and follow-up strategies. This study aims to identify risk factors associated with recurrence of PanNETs and to develop a clinically applicable risk stratification tool based on multi-center cohorts and multi-omics validation for identifying high-risk patients.
Official title: A Clinically Applicable Risk Score for Identifying High-risk Pancreatic Neuroendocrine Tumors: Development, Validation, and Biological Correlates
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
552
Start Date
2017-06-01
Completion Date
2026-07-01
Last Updated
2026-07-10
Healthy Volunteers
No
Conditions
Interventions
Curative surgical resection
After pathological confirmation of pancreatic neuroendocrine neoplasm, the patient underwent radical surgery.
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China